Could Ozempic and other GLP-1 drugs help you live longer?
Early research suggests GLP-1 drugs like Ozempic may one day support a longer life by slowing biological aging markers and reducing risks tied to heart disease and diabetes. Scientists have not proven these medications extend lifespan in otherwise healthy people, and experts caution against taking them off-label solely for longevity.
Weight-loss medications including Ozempic and Zepbound have reshaped how doctors treat obesity and diabetes. Now researchers are asking whether these drugs could also work as longevity treatments—a question drawing intense interest in the longevity and biohacking space.
According to The New York Times, the answer could eventually be yes, but the evidence is not there yet.
Key Takeaways
- Adults with HIV who took semaglutide for eight months showed signs of slower biological aging in an early study led by UC San Diego researcher Michael Corley.
- GLP-1 drugs already reduce major drivers of early death, including heart disease and diabetes, which some experts say could translate into longer lives.
- There is little evidence that Ozempic and similar drugs extend lifespan in otherwise healthy people.
- Scientists worry about muscle loss and lower bone density—side effects that could matter more as patients age.
- Several trials measuring aging, inflammation, strength, and mobility are underway, but results remain years away.
What did the new Ozempic aging study find?
One of the first human trials to probe longevity effects found that adults with HIV who took semaglutide—the active ingredient in Ozempic—for eight months showed signs of slower biological aging based on blood biomarkers. Michael Corley, PhD, an associate professor at UC San Diego's Stein Institute for Research on Aging, led the work.
A related study published in Nature Communications examined adults with HIV-associated lipohypertrophy over 32 weeks. Though aging was not the original endpoint, post-hoc analysis found promising signals for inflammation, plus heart and brain aging markers, as Inc. reported. Because of the narrow patient group and post-hoc design, scientists caution the findings are difficult to generalize.
Corley told the Times the trial was a first step: "The trial provided us an opportunity to say, hey, is there any signal here that warrants all the hype?"
Why are researchers interested in GLP-1 drugs?
Scientists already know GLP-1 medications improve metabolic health, lower blood sugar, promote weight loss, and reduce the risk of conditions like heart disease and diabetes—two of the leading causes of death. As Inc. noted, the CDC lists both among America's top 10 causes of death, meaning drugs that treat them could arguably already function as longevity medicines by keeping people healthier.
Researchers also believe GLP-1 drugs may influence biological pathways tied to aging. They appear to reduce chronic inflammation, long linked to faster aging and age-related disease. Nicolas Musi, MD, director of the Diabetes and Aging Center at Cedars-Sinai, told the Times that because these drugs curb diseases associated with aging, it is reasonable to think they could eventually improve longevity.
Should you take Ozempic just to live longer?
Not yet, experts say. Despite growing excitement, there is little evidence that GLP-1 drugs extend lifespan in otherwise healthy people. Scientists also remain concerned about side effects that could matter as people age, including muscle loss and lower bone density, both of which can increase frailty risk.
Dr. Musi told the Times he does not recommend taking GLP-1 drugs off-label solely to live longer. If you are considering a GLP-1 medication, talk with your doctor about whether you meet approved medical criteria rather than using it only to manage aging.
What happens next?
Several clinical trials are now underway to measure whether these medications affect biological aging, inflammation, strength, and mobility, though results are still years away. Inc. reported that more trials studying aging markers and functional abilities are expected to begin shortly.
For now, researchers say it is too early to call Ozempic and its GLP-1 cousins longevity drugs. They continue to show promise beyond weight loss—but confirming whether they help anyone live longer will require larger, longer studies with broader populations.